Delray Medical Center Advances its Endovascular Program as the First Hospital in Florida to Acquire the AI-Powered Viz Vascular Suite

As a leader in vascular care, Delray Medical Center is the first hospital in Florida to acquire the Viz Vascular Suite.  This is a comprehensive software its vascular care team can use to detect disease, optimize workflow, and coordinate care.

The Viz Vascular Suite uses artificial intelligence (AI) to automatically detect suspected pulmonary embolism, right/left ventricle dilation, aortic dissection, and abdominal aortic aneurysm to facilitate informed and efficient treatment decisions.

“Being able to identify a patient with a serious vascular condition, such as an abdominal aortic aneurysm, early – before they have an emergency, is a game changer and literally a lifesaver,” said Dr. Joseph Ricotta, professor of surgery and program director of the vascular surgery fellowship at Florida Atlantic University College of Medicine, and national medical director of vascular surgery and endovascular therapy at Tenet Healthcare. “For example, there are roughly 1.5 million abdominal aortic aneurysms in the US per year; however, only 10 percent get diagnosed and treated. We don’t often find out about them until it’s too late and, even then, there’s only a 25 percent chance of living through a ruptured aortic aneurysm. From my experience as an early adopter of this technology, the Viz Vascular Suite will help enhance screening and coordinate care across my vascular team.”

The Viz Vascular Suite is designed to automatically analyze imaging and data and, in turn, eliminate futile patient transfers between departments and decrease the time patients spend in the emergency department. Using the Viz.ai platform, care can be coordinated for any vascular pathology, and managed remotely within a hub and spoke network, which expedites diagnosis and treatment.  It also aids Delray Medical Center in activating its Pulmonary Embolism Response Team (PERT), which is a multidisciplinary team that rapidly assesses and provides treatment for patients with acute pulmonary embolism.

“We set out to build a solution where any patient with life-threatening, vascular diseases can benefit from AI-powered triage, fast mobile communication and synchronized care coordination,” said Gad Sakin, chief product officer at Viz.ai. “The Viz Vascular Suite is designed to bring the advantages of intelligent care coordination to even more patients and help clinical teams, like the one at Delray Medical Center, achieve better clinical outcomes.”

In addition to the latest acquisition of the Viz Vascular Suite, Delray Medical Center is utilizing the technology for an investigational study using the AlphaVac Multipurpose Mechanical Aspiration (MMA) F1885 system in the treatment of acute pulmonary embolism.  The purpose of this study is to evaluate the safety and effectiveness of percutaneous mechanical aspiration thrombectomy using the AlphaVac Multipurpose Mechanical Aspiration (MMA) F1885 PE in a prospective trial of patients with acute intermediate-risk pulmonary embolism.

Remaining on the forefront of new technology and treatments has been a hallmark of the vascular program at Delray Medical Center as it was the first in the country to perform endovascular robotic surgery, the first in Florida to perform trans-carotid revascularization (TCAR) for the treatment of carotid artery disease and stroke, the first in Florida to perform Venaseal TM for the treatment of venous disease, and the first in Palm Beach county to perform intravascular lithotripsy balloon angioplasty for peripheral vascular disease. Rounding out Delray Medical Center’s endovascular program are a Limb Preservation Program, a new Hybrid Endovascular OR Suite, the CorPath system for robotic-assisted vascular interventions, and the Artis pheno, which is a robotic C-arm angiography system for use in minimally invasive interventional procedures that improves flexibility in the OR by expanding patient access, reducing radiation and maintaining an uninterrupted sterile airflow with antimicrobial surfaces. Equipped with advanced, robotic surgical technology not available at any other hospital in Palm Beach County, the experienced team of physicians and surgeons at Delray Medical Center offer even more minimally invasive vascular interventional procedures to patients, including specialized procedures that are designed to spare tissue, repair damage and help maintain and restore function in limbs that would otherwise have to be amputated.

Other conditions treated include:

  • Aortic Aneurysm
  • Carotid Artery Disease
  • Deep Vein Thrombosis/Pulmonary Embolism
  • Diabetic Peripheral Neuropathy
  • Diabetic Ulcers/Wounds
  • Mesenteric and Renal Disease
  • Pelvic Congestion Syndrome and Thoracic Outlet Syndrome
  • Peripheral Vascular Disease/Peripheral Arterial Disease
  • Vascular Malformations
  • Venous Disease
  • Dialysis Access

For more information about the Endovascular Program at Delray Medical Center, log on to Endovascular Robotics Surgery Delray Beach, FL | Delray Medical Center (delraymedicalctr.com)

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”